Krystal Biotech Inc
NASDAQ:KRYS
Balance Sheet
Balance Sheet Decomposition
Krystal Biotech Inc
Krystal Biotech Inc
Balance Sheet
Krystal Biotech Inc
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
50
|
104
|
188
|
268
|
341
|
162
|
358
|
345
|
496
|
|
| Cash Equivalents |
2
|
50
|
104
|
188
|
268
|
341
|
162
|
358
|
345
|
496
|
|
| Short-Term Investments |
0
|
0
|
8
|
6
|
3
|
97
|
217
|
174
|
253
|
331
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
42
|
105
|
127
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
42
|
105
|
127
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
27
|
40
|
|
| Other Current Assets |
0
|
0
|
1
|
2
|
4
|
4
|
5
|
7
|
13
|
29
|
|
| Total Current Assets |
2
|
50
|
113
|
196
|
275
|
442
|
384
|
588
|
742
|
1 025
|
|
| PP&E Net |
0
|
0
|
3
|
11
|
34
|
120
|
170
|
168
|
161
|
158
|
|
| PP&E Gross |
0
|
0
|
3
|
11
|
34
|
120
|
170
|
168
|
161
|
158
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
2
|
4
|
7
|
13
|
22
|
31
|
|
| Long-Term Investments |
0
|
0
|
0
|
1
|
0
|
64
|
5
|
62
|
152
|
128
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
2
|
2
|
0
|
0
|
0
|
0
|
23
|
|
| Total Assets |
2
N/A
|
50
+2 177%
|
116
+132%
|
209
+80%
|
311
+49%
|
626
+102%
|
559
-11%
|
818
+47%
|
1 056
+29%
|
1 334
+26%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
1
|
1
|
2
|
8
|
4
|
4
|
5
|
3
|
|
| Accrued Liabilities |
0
|
0
|
2
|
3
|
6
|
17
|
25
|
24
|
90
|
85
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
8
|
0
|
0
|
4
|
7
|
14
|
|
| Total Current Liabilities |
0
|
1
|
3
|
3
|
16
|
26
|
29
|
33
|
102
|
103
|
|
| Long-Term Debt |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
3
|
3
|
7
|
7
|
7
|
7
|
11
|
|
| Total Liabilities |
2
N/A
|
1
-68%
|
3
+383%
|
6
+110%
|
19
+208%
|
33
+74%
|
36
+11%
|
40
+10%
|
109
+176%
|
114
+4%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
9
|
20
|
39
|
71
|
141
|
281
|
270
|
181
|
24
|
|
| Additional Paid In Capital |
0
|
59
|
133
|
242
|
363
|
735
|
804
|
1 048
|
1 127
|
1 194
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
|
| Total Equity |
0
N/A
|
50
+16 400%
|
113
+129%
|
203
+79%
|
292
+44%
|
594
+103%
|
522
-12%
|
779
+49%
|
946
+22%
|
1 220
+29%
|
|
| Total Liabilities & Equity |
2
N/A
|
50
+2 177%
|
116
+132%
|
209
+80%
|
311
+49%
|
626
+102%
|
559
-11%
|
818
+47%
|
1 056
+29%
|
1 334
+26%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
9
|
10
|
14
|
17
|
20
|
25
|
26
|
28
|
29
|
29
|
|